A SPAC III Acquisition Corp
ASPAC III Acquisition Corp. is a special purpose acquisition company, or blank check company, formed to complete a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination. The company does not operate a commercial business of its own and has not generated operating revenue to date. Instead, it holds IPO and private placement proceeds in trust while searching for a target company to take public. Management has stated a preference for growth businesses in the ESG and material technology markets, with an enterprise value target range of roughly $100 million to $600 million. In 2025, the company announced and later signed a merger agreement with Bioserica, a bio-based antimicrobial materials business, after an earlier indication of interest with HD Group was terminated.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueA blank-check public company structure used to raise cash in an IPO and private placement for a future acquisition.
Transaction structuring, negotiation, and closing services related to merging with a target operating company.
Customers
ASPAC III does not sell products to end customers in the normal operating sense; its counterparties are target businesses, sponsors, and public shareholders. The company is looking for growth businesses that want access to public capital markets and can benefit from a merger transaction rather than a traditional IPO. Its stated target profile emphasizes companies with defensible products, strong management teams, and public-readiness, especially in ESG and material technology. In practice, the 'customer' for the SPAC structure is the private company seeking a listing path, while public investors provide the capital and optionality. The announced Bioserica transaction shows the company’s focus on operating businesses with industrial or sustainability-linked applications.
Private companies that may merge with the SPAC to access public equity capital and a public listing.
IPO investors who buy units for exposure to the trust account and optional upside from a successful business combination.
The sponsor provides private placement capital and supports the transaction process and working capital needs.
Third-party investors that may provide additional capital at closing to help fund the acquisition.
Strategy
ASPAC III’s strategy is to complete an initial business combination with a growth company that has defensible products, strong management, and a clear path to benefit from public-market capital. Management has specifically highlighted ESG and material technology as preferred sectors, suggesting a thematic sourcing approach rather than a broad industry mandate. The company also appears to favor targets that are public-ready and can use the SPAC structure to accelerate growth and shareholder value creation. The 2025 merger agreement with Bioserica shows the strategy in action, moving from target screening to a signed transaction in a sustainability-linked materials business. The company must balance deal quality with the finite combination period, making execution speed and financing certainty central to the strategy.
The SPAC has no operating business until it completes a merger, so transaction execution is the core value-creation event.
Management has identified these sectors as the preferred hunting ground for differentiated growth businesses.
The company needs enough capital and structuring flexibility to complete a merger and support the combined company.
Geography
The company is incorporated in the British Virgin Islands but maintains executive offices in Hong Kong, reflecting an Asia-linked operating base. Its trust account is located in the United States and invested in U.S. government securities, which ties the cash structure to U.S. capital markets. The company’s announced and pursued targets have included businesses headquartered in China and the British Virgin Islands, indicating a cross-border acquisition strategy. Because ASPAC III is a SPAC, geography matters less through sales distribution and more through where targets are headquartered, where the transaction is structured, and where the trust assets are held. The company’s exposure is therefore concentrated in U.S. listing rules, Hong Kong-based management operations, and Asia-focused deal sourcing.
Risks
The company’s main risk is that it may fail to complete a business combination before the end of the combination period, which would force liquidation or redemption of public shares. Deal execution risk is elevated because SPACs face intense competition for attractive targets, and target companies may be deterred by shareholder approval requirements, listing uncertainty, and dilution from rights and warrants. The company also faces financing and valuation risk because it must structure a transaction that is acceptable to the target while preserving enough capital for the post-merger business. More broadly, SPACs are exposed to regulatory, market, and sentiment risk, including changes in Nasdaq requirements, redemption pressure, and weaker investor appetite for de-SPAC transactions. Cross-border target sourcing adds additional legal, disclosure, and execution complexity, especially when targets are linked to China or other non-U.S. jurisdictions.
A SPAC has no operating revenue until it closes a merger, so missing the deadline can trigger liquidation or shareholder redemptions.
Exposure: Company-level survival and value realization
Other SPACs and acquisition sponsors may bid for the same attractive growth businesses, limiting the company’s ability to win deals.
Exposure: Deal sourcing and valuation
Nasdaq may require a new listing application or additional conditions after a business combination, which can delay or block closing.
Exposure: Transaction completion and post-close trading status
Public rights and unit purchase options can dilute future shareholders and make some targets less willing to transact.
Exposure: Post-merger ownership and deal attractiveness
Targets in China, the BVI, or other non-U.S. jurisdictions can create legal, governance, and disclosure challenges.
Exposure: Target diligence and closing mechanics
Accounting
Judgemental itemsThis is the core SPAC accounting issue and determines whether public shares are treated as equity or temporary equity/liability-like instruments.
Impact: Affects balance sheet classification, book value, and per-share metrics
Interest earned on U.S. Treasury or money market investments is the main recurring income source before a merger closes.
Impact: Drives reported net income despite no operating business
Underwriting commissions, representative shares, and other IPO costs are significant relative to the company’s size.
Impact: Can materially affect reported earnings and equity around the IPO period
SPAC share counts and sponsor forfeitures can make per-share calculations non-intuitive.
Impact: Affects comparability across periods and with post-merger companies
Similar listed companies
Publicly listed companies with a comparable business focus.
Aspac Ii Acquisition Corp.
ASCRF · Blank Checks
BEST SPAC I Acquisition Corp
BSAAU · Services-Educational Services
Black Hawk Acquisition Corp
BKHAR · Biological Products, (No Diagnostic Substances)
Black Hawk Acquisition Corp is a U.S.-listed blank check company formed to complete a merger, share exchange, asset acquisition, stock purchase,…
Blue Water Acquisition Corp. III
BLUW · Blank Checks
Blue Water Acquisition Corp.
Dynamix Corp III
DNMXW · Blank Checks
Dynamix Corp III is a special purpose acquisition company (SPAC) formed to complete a merger, share exchange, asset acquisition, or similar business combination with an operating business.
Cartica Acquisition Corp
Blank Checks
Cartica Acquisition Corp is a special purpose acquisition company formed in the Cayman Islands to complete a business combination with one or more operating businesses.
Last updated: 24/09/2026